ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1638

Impact of Extra-Articular Manifestations on Patient-Reported Outcomes in Ankylosing Spondylitis and Psoriatic Arthritis: Interim Results from the Complete Studies

Louis Bessette1, Majed Khraishi2,3, Brandusa Florica4, Yatish Setty5, Michelle Teo6 and Valencia P. Remple7, 1Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, 2Memorial University of Newfoundland, St. John's, NF, Canada, 3Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, 4University of Toronto, Toronto, ON, Canada, 5Grey Bruce Health Services, Owen Sound, ON, Canada, 6University of British Columbia, Penticton, BC, Canada, 7AbbVie Corporation, Montreal, QC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adalimumab, Ankylosing spondylitis (AS), extraarticular manifestations, patient-reported outcome measures and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Extra-articular manifestations (EAMs) in rheumatic diseases have been previously found to negatively impact health outcomes including quality of life and work capacity. Even though EAMs may be directly associated with worse response to treatment, differences in patient-reported outcomes (PROs) based on the presence of EAMs could be an important contributory variable. The objective of this study was to assess the impact of EAMs on PROs among patients with active AS or PsA followed in Canadian routine clinical care.

Methods: Patients eligible for the COMPLETE studies are anti-TNFα naïve adults, with active AS or PsA per the judgment of the treating physician, who require change in their treatment regimen. In the current analysis, patients enrolled between July 2011 and June 2017 were included. The EAMs were defined as the presence of the following at baseline: enthesitis, uveitis, IBD or psoriasis (EAMAS1 for AS); enthesitis, uveitis, or IBD (EAMAS2 for AS); enthesitis or dactylitis (EAMPsA for PsA). The PROs included the Short Form Health Survey (SF-12), Work Limitations Questionnaire (WLQ), and Beck’s Depression Inventory (BDI). The PROs were compared between patients with and without EAMs using the independent samples t-test. The independent association between presence of EAMs and PROs at baseline was assessed with multivariate generalized linear models adjusting for disease state (high/very high vs. inactive/low/moderate disease based on the BASDAI for AS and the DAS28 for PsA), disease type, and ever smoking.

Results:

A total of 609 AS and 406 PsA patients were included with a mean (SD) age of 43.1 (13.4) and 51.3 (12.3) years, respectively. The EAMAS1 and EAMAS2 prevalence among AS patients was 33.9% and 25%, respectively, while among PsA patients EAMPsA prevalence was 45.4%.

In univariate analysis, presence of EAMs in AS was associated with significantly higher disease activity, BDI total score, WLQ mental interpersonal demands (only for EAMAS1), WLQ physical demands, WLQ time demands, SF-12 physical function, SF-12 role physical, SF-12 bodily pain, SF-12 vitality, SF-12 mental health (only for EAMAS1), and the SF-12 physical component summary score (PCS). Among PsA patients, patients with EAMPsA had higher disease activity but no significant association was observed between EAMPsA and PROs.

Upon adjusting for disease state, disease type, and ever smoking, presence of EAMAS1/EAMPsA for AS/PsA patients was associated with significantly higher BDI total score (14.0 vs. 12.6, p=0.046) and lower SF-12 physical function (38.4 vs. 44.8, p=0.047). When evaluating the impact of EAMAS2/EAMPsA for AS/PsA patients no significant differences were observed in PROs; however, BDI was notably higher among patients with EAMs (14.1 vs. 12.7, p=0.056).

Conclusion: In a Canadian routine clinical care setting, a substantial proportion of AS and PsA patients requiring a change in treatment report EAMs. Presence of EAMs, particularly psoriasis for AS patients, was found to be a significant independent predictor of depressive symptoms and reduced quality of life due to worse physical functioning.


Disclosure: L. Bessette, Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Lilly, Novartis, 2, 5, 8; M. Khraishi, AbbVie Inc., 2, 5, 8; B. Florica, Janssen, Merck, Abbvie, Roche, BMS, Novartis, Pfizer, Celgene, UCB, 2, 5, 8; Y. Setty, AbbVie Inc., 5; M. Teo, AbbVie, Amgen, Celgene, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi-Genzyme UCB, 5, 8; V. P. Remple, AbbVie Inc., 1.

To cite this abstract in AMA style:

Bessette L, Khraishi M, Florica B, Setty Y, Teo M, Remple VP. Impact of Extra-Articular Manifestations on Patient-Reported Outcomes in Ankylosing Spondylitis and Psoriatic Arthritis: Interim Results from the Complete Studies [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/impact-of-extra-articular-manifestations-on-patient-reported-outcomes-in-ankylosing-spondylitis-and-psoriatic-arthritis-interim-results-from-the-complete-studies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-extra-articular-manifestations-on-patient-reported-outcomes-in-ankylosing-spondylitis-and-psoriatic-arthritis-interim-results-from-the-complete-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology